Kapasite enstitisyonèl pou pran desizyon transparan nan defini priyorite yo

aspects of data analysis and utilization, and implement monitoring and evaluation. In producing global public health goods, the Secretariat will: develop norms and standards, for example, by creating an expanded repository of health interventions, as recommended by WHO technical programmes, which include information on inputs, effectiveness, service delivery arrangements, economic benefits and resource requirements, and by making the expanded repository available through an online platform; by developing guidance on the procedural aspects of using data to support health benefit package selection and promote best practices; and by continuously updating and expanding the Universal Health Coverage Compendium to support health sector decision-making and planning processes; create or refine tools to estimate costs, health impacts, cost-effectiveness and economic returns associated with investing in the health system in support of universal health coverage, including the One Health tool (costing), WHO-CHOICE (cost-effectiveness analysis), EPIC (impact on the national economy) and AccessMod (geographical accessibility to health services), and to support evidence-based allocation of resources, such as facilities and health workforce, according to population distribution; develop new models for building country capacity, including mentorship, using networks of partners and online learning modules designed to sequentially and progressively build technical skills; create research products, for example, by using and advancing robust scientific methods to produce technically defensible estimates of the economic impact of changes in health status, identify how changes in health status affect labour markets and labour supply and economic growth, and determine the impact of growth in the health sector on the economy as a whole; produce new analyses or updates of global price tags and investment cases extending to macroeconomic impact; develop new or updated generic models of cost-effectiveness analysis and other forms of economic or impact evaluation to inform best buys, incorporating equity outcomes where possible; develop and test new methodologies, including dynamic modelling, microsimulation and projections and scenario generation, with relevant partners; refine guidance on priority-setting and selection processes for health benefit packages, including health intervention and technology assessment; and produce guidance on technical efficiency analysis to support value-for-money considerations.